Technology transfer / Localization · MENA · Announced 15 Nov 2025

Bayer → Minapharm Pharmaceuticals

Bayer and Minapharm signed a cooperation agreement, witnessed by the Egyptian Drug Authority, to localize pharmaceutical manufacturing in Egypt with a focus on women's and reproductive health and family planning.

Parties: Bayer (Germany) → Minapharm Pharmaceuticals (Egypt)

Value
Undisclosed
Territory
Egypt, with export to regional and African markets
Therapeutic area
Women's Health
Asset
Women's health and family planning portfolio (products not named)
Announced
15 Nov 2025

Our analysis

Why this matters

Minapharm Pharmaceuticals and Bayer signed a cooperation agreement on 15 November 2025 to localize pharmaceutical manufacturing in Egypt. The signing took place in the New Administrative Capital under the auspices of Deputy Prime Minister and Minister of Health and Population Khaled Abdel Ghaffar, alongside the Global Conference on Population, Health and Development, and was witnessed by the Egyptian Drug Authority (EDA). The EDA chairman described it as a step towards localizing the industry and transferring advanced technologies. Products, value and timelines were not disclosed.

The focus is women's health, reproductive health and family planning, tied to the Presidential Initiative for Egyptian Women's Health and Egypt's National Strategy for Population and Development 2023–2030. Egypt is positioned as a hub for regional and African export.

The full analysis is free to read with a work email on this page.

Source: Egyptian Drug Authority

More deals involving Bayer or Minapharm Pharmaceuticals

Latest deals

All MENA deals → · All technology transfer / localization deals → · Browse all emerging-market pharma deals →